Division of Neoplastic Diseases, Medical College of Wisconsin, Milwaukee, WI, USA.
Leuk Res. 2010 Jul;34(7):950-3. doi: 10.1016/j.leukres.2010.02.034. Epub 2010 Mar 24.
Combination chemotherapy forms the backbone of cancer treatment. There is a need for new drug combinations for the treatment of mantle cell lymphoma (MCL). Herein, we show that gallium maltolate, a novel gallium compound, synergizes with bortezomib, a proteasome inhibitor, to induce cell death in MCL Granta cells. Cells exposed to either agent displayed caspase-3 activation, a loss of mitochondrial membrane potential, and a decrease in chymotrypsin-like activity. These effects were increased with both agents in combination. Our results show for the first time that the proteasome may be a target for gallium maltolate and suggest that the therapeutic potential of combination bortezomib and gallium maltolate warrants further investigation.
联合化疗是癌症治疗的基础。目前需要新的药物组合来治疗套细胞淋巴瘤（MCL）。本研究显示，新型镓化合物甘氨双唑钠与蛋白酶体抑制剂硼替佐米联合应用可诱导 MCL Granta 细胞死亡。两种药物单独或联合作用均可导致 caspase-3 激活、线粒体膜电位丧失和糜蛋白酶样活性降低。结果首次表明蛋白酶体可能是甘氨双唑钠的作用靶点，并提示硼替佐米与甘氨双唑钠联合应用具有潜在的治疗价值，值得进一步研究。
